Pharming Group (Pharming Group) 5-Year EBITDA Growth Rate

: -19.10% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Pharming Group's EBITDA per Share for the three months ended in Dec. 2023 was $0.08.

During the past 12 months, Pharming Group's average EBITDA Per Share Growth Rate was -73.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -44.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pharming Group was 66.30% per year. The lowest was -109.60% per year. And the median was 16.50% per year.

Competitive Comparison

For the Biotechnology subindustry, Pharming Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group 5-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Pharming Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharming Group's 5-Year EBITDA Growth Rate falls into.

Pharming Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Pharming Group (NAS:PHAR) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Pharming Group 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharming Group's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group (Pharming Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.